You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePerampanel
Accession NumberDB08883
TypeSmall Molecule
GroupsApproved
DescriptionPerampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
Structure
Thumb
Synonyms
3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
perampanel
pérampanel
Perampanelum
External Identifiers
  • E-2007
  • E2007
  • ER-155055-90
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fycompatablet2.0 mgoralEisai Limited2013-06-19Not applicableCanada
FycompaFilm-coated tablet8 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet2 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompakitEisai Inc.2012-10-22Not applicableUs
FycompaFilm-coated tablet4 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet8.0 mgoralEisai Limited2013-06-19Not applicableCanada
FycompaFilm-coated tablet12 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet8 mg/1oralEisai Inc.2012-10-22Not applicableUs
FycompaFilm-coated tablet6 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet10 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet10 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet12.0 mgoralEisai Limited2013-05-17Not applicableCanada
Fycompatablet2 mg/1oralEisai Inc.2012-10-22Not applicableUs
FycompaFilm-coated tablet4 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet4 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet10.0 mgoralEisai Limited2013-06-03Not applicableCanada
FycompaFilm-coated tablet12 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet10 mg/1oralEisai Inc.2012-10-22Not applicableUs
FycompaFilm-coated tablet8 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet12 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet4.0 mgoralEisai Limited2013-06-19Not applicableCanada
FycompaFilm-coated tablet10 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet4 mg/1oralEisai Inc.2012-10-22Not applicableUs
FycompaFilm-coated tablet6 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet6 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet2 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet12 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet12 mg/1oralEisai Inc.2012-10-22Not applicableUs
FycompaFilm-coated tablet8 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet6.0 mgoralEisai Limited2013-06-19Not applicableCanada
FycompaFilm-coated tablet10 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Fycompatablet6 mg/1oralEisai Inc.2012-10-22Not applicableUs
FycompaFilm-coated tablet6 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet8 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet4 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
FycompaFilm-coated tablet2 mgOral useEisai Europe Ltd2012-07-23Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Perampanel hydrate
1571982-04-1
Thumb
  • InChI Key: PDWMJDKMSASBNE-UHFFFAOYSA-N
  • Monoisotopic Mass: 1450.517742513
  • Average Mass: 1451.617
DBSALT001824
Categories
UNIIH821664NPK
CAS number380917-97-5
WeightAverage: 349.393
Monoisotopic: 349.121512115
Chemical FormulaC23H15N3O
InChI KeyPRMWGUBFXWROHD-UHFFFAOYSA-N
InChI
InChI=1S/C23H15N3O/c24-15-17-8-4-5-11-20(17)21-14-18(22-12-6-7-13-25-22)16-26(23(21)27)19-9-2-1-3-10-19/h1-14,16H
IUPAC Name
2-{6'-oxo-1'-phenyl-1',6'-dihydro-[2,3'-bipyridine]-5'-yl}benzonitrile
SMILES
O=C1N(C=C(C=C1C1=CC=CC=C1C#N)C1=NC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassBipyridines and oligopyridines
Direct ParentBipyridines and oligopyridines
Alternative Parents
Substituents
  • Bipyridine
  • 3-phenylpyridine
  • Benzonitrile
  • Dihydropyridine
  • Pyridinone
  • Monocyclic benzene moiety
  • Hydropyridine
  • Benzenoid
  • Heteroaromatic compound
  • Lactam
  • Nitrile
  • Carbonitrile
  • Azacycle
  • Organooxygen compound
  • Organonitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Cyanide
  • Organic oxygen compound
  • Organic nitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.
PharmacodynamicsPerampanel is involved in inhibiting neuronal excitation in the central nervous system leading to such effects as decreased pyschomotor performance.
Mechanism of actionThe exact mechanism of action of perampanel in seizures is not yet determined, but it is known that perampanel decreases neuronal excitation by non-competitive ihibition of the AMPA receptor.
Related Articles
AbsorptionAfter oral adminitration, perampanel is absorbed rapidly and completely.
Volume of distribution

The volume of distribution of perampanel was not quantified.

Protein bindingPerampanel is 95-96% plasma protein bound with most binding to the plasma proteins α1-acid glycoprotein and albumin.
Metabolism

Perampanel is highly metabolized by CYP3A4 and/or CYP3A5 primary oxidation and by sequential glucuronidation.

Route of eliminationPerampanel is eliminated mostely in the feces (48%) and to a lesser exten in the urine (22%).
Half lifePerampanel has a long elmination half-life of about 105 hours.
Clearance

In healthy patients, perampanel has a clearance of about 12 mL/min.

ToxicityThe FDA label includes an important warning of serious or life-threatening behavioral and psychiatric adverse reactions including aggression, hostility, irritability, anger, and homicidal thoughts in patients taking perampanel.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Film-coated tabletOral use10 mg
Film-coated tabletOral use12 mg
Film-coated tabletOral use2 mg
Film-coated tabletOral use4 mg
Film-coated tabletOral use6 mg
Film-coated tabletOral use8 mg
Kit
Tabletoral10 mg/1
Tabletoral10.0 mg
Tabletoral12 mg/1
Tabletoral12.0 mg
Tabletoral2 mg/1
Tabletoral2.0 mg
Tabletoral4 mg/1
Tabletoral4.0 mg
Tabletoral6 mg/1
Tabletoral6.0 mg
Tabletoral8 mg/1
Tabletoral8.0 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6949571 No2001-06-082021-06-08Us
US8772497 No2006-05-162026-05-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityPractically insoluble in water.From FDA label.
Predicted Properties
PropertyValueSource
Water Solubility0.0056 mg/mLALOGPS
logP3.54ALOGPS
logP4.11ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)4.01ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.99 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.74 m3·mol-1ChemAxon
Polarizability38.03 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Francesco Fontana, “METHODS FOR PREPARING INTERMEDIATES OF PERAMPANEL.” U.S. Patent US20130109862, issued May 02, 2013.

US20130109862
General References
  1. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y: Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011 Jul;52(7):1331-40. doi: 10.1111/j.1528-1167.2011.03109.x. Epub 2011 Jun 2. [PubMed:21635236 ]
External Links
ATC CodesN03AX22
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (611 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Perampanel.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Perampanel.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Perampanel.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Perampanel.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Perampanel.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Perampanel.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Perampanel.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Perampanel.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Perampanel.
AmiodaroneThe metabolism of Perampanel can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Perampanel.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Perampanel.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Perampanel.
AmoxapineThe risk or severity of adverse effects can be increased when Perampanel is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Perampanel.
AprepitantThe serum concentration of Perampanel can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perampanel.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Perampanel.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Perampanel.
AtazanavirThe metabolism of Perampanel can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Perampanel can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Perampanel.
AzelastinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Perampanel.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Perampanel.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Perampanel.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Perampanel.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Perampanel.
BexaroteneThe serum concentration of Perampanel can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Perampanel can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Perampanel can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Perampanel can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Perampanel is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
BrimonidineThe risk or severity of adverse effects can be increased when Perampanel is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Perampanel.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Perampanel.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Perampanel.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Perampanel.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Perampanel.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Perampanel.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Perampanel.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Perampanel.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Perampanel.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Perampanel.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Perampanel.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Perampanel.
CarbamazepineThe serum concentration of Perampanel can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Perampanel is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Perampanel.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Perampanel.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Perampanel.
CeritinibThe serum concentration of Perampanel can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Perampanel.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Perampanel.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Perampanel.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Perampanel.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Perampanel.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Perampanel.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Perampanel.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perampanel.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Perampanel.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Perampanel.
CitalopramThe risk or severity of adverse effects can be increased when Perampanel is combined with Citalopram.
ClarithromycinThe metabolism of Perampanel can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Perampanel can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Perampanel is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Perampanel.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Perampanel.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Perampanel.
ClomipramineThe risk or severity of adverse effects can be increased when Perampanel is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Perampanel.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Perampanel.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Perampanel.
ClotrimazoleThe metabolism of Perampanel can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Perampanel.
CobicistatThe metabolism of Perampanel can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Perampanel.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Perampanel.
ConivaptanThe serum concentration of Perampanel can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Perampanel can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Perampanel.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perampanel.
CyclosporineThe metabolism of Perampanel can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Perampanel.
DabrafenibThe serum concentration of Perampanel can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Perampanel.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Perampanel.
DapoxetineThe risk or severity of adverse effects can be increased when Perampanel is combined with Dapoxetine.
DarunavirThe metabolism of Perampanel can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Perampanel can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Perampanel can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Perampanel can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Perampanel.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Perampanel.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Perampanel.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Perampanel.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Perampanel.
DexamethasoneThe serum concentration of Perampanel can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Perampanel.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perampanel.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Perampanel.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Perampanel.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Perampanel.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Perampanel.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Perampanel.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Perampanel.
DihydroergotamineThe metabolism of Perampanel can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Perampanel.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Perampanel.
DiltiazemThe metabolism of Perampanel can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Perampanel.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Perampanel.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Perampanel.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Perampanel.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Perampanel.
DoxycyclineThe metabolism of Perampanel can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
DoxylamineThe risk or severity of adverse effects can be increased when Perampanel is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Perampanel.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
DronedaroneThe metabolism of Perampanel can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Perampanel.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Perampanel.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Perampanel.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Perampanel.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Perampanel.
EfavirenzThe serum concentration of Perampanel can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Perampanel is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Perampanel.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Perampanel.
EnzalutamideThe serum concentration of Perampanel can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Perampanel can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Perampanel is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Perampanel can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Perampanel.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Perampanel.
EthanolPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Perampanel.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Perampanel.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Perampanel.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Perampanel.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Perampanel.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Perampanel.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Perampanel.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Perampanel.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Perampanel.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Perampanel.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Perampanel.
EtoperidoneThe risk or severity of adverse effects can be increased when Perampanel is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Perampanel.
EtravirineThe serum concentration of Perampanel can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Perampanel.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Perampanel.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Perampanel.
FenfluramineThe risk or severity of adverse effects can be increased when Perampanel is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Perampanel.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Perampanel.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Perampanel.
FluconazoleThe metabolism of Perampanel can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Perampanel.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Perampanel.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Perampanel.
FluoxetineThe risk or severity of adverse effects can be increased when Perampanel is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Perampanel.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Perampanel.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Perampanel.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Perampanel.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Perampanel.
FluvoxamineThe risk or severity of adverse effects can be increased when Perampanel is combined with Fluvoxamine.
FluvoxamineThe metabolism of Perampanel can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Perampanel can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Perampanel can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Perampanel can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Perampanel is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Perampanel.
Fusidic AcidThe serum concentration of Perampanel can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Perampanel.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Perampanel.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Perampanel.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Perampanel.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Perampanel.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Perampanel.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perampanel.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Perampanel.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Perampanel.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Perampanel.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Perampanel.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Perampanel.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Perampanel.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
HydroxyzineThe risk or severity of adverse effects can be increased when Perampanel is combined with Hydroxyzine.
IdelalisibThe serum concentration of Perampanel can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Perampanel.
ImatinibThe metabolism of Perampanel can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Perampanel.
IndalpineThe risk or severity of adverse effects can be increased when Perampanel is combined with Indalpine.
IndinavirThe metabolism of Perampanel can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Perampanel can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Perampanel.
IsradipineThe metabolism of Perampanel can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Perampanel can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Perampanel can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Perampanel.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Perampanel.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Perampanel.
KetoconazoleThe metabolism of Perampanel can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Perampanel.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Perampanel.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Perampanel.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Perampanel.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Perampanel.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Perampanel.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Perampanel.
LevomilnacipranThe risk or severity of adverse effects can be increased when Perampanel is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Perampanel.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Perampanel.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Perampanel.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Perampanel.
LopinavirThe metabolism of Perampanel can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Perampanel.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Perampanel.
LovastatinThe metabolism of Perampanel can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Perampanel.
Lu AA21004The risk or severity of adverse effects can be increased when Perampanel is combined with Lu AA21004.
LuliconazoleThe serum concentration of Perampanel can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Perampanel.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Perampanel is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Perampanel.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Perampanel.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Perampanel.
MefloquineThe therapeutic efficacy of Perampanel can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Perampanel.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Perampanel.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Perampanel.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perampanel.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Perampanel.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Perampanel.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Perampanel.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Perampanel.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Perampanel.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Perampanel.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Perampanel.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Perampanel.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Perampanel.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Perampanel.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Perampanel.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Perampanel.
MetyrosinePerampanel may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Perampanel can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Perampanel.
MifepristoneThe metabolism of Perampanel can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Perampanel is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
MirtazapinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Perampanel.
MitotaneThe serum concentration of Perampanel can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Perampanel can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Perampanel.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Perampanel.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
NabiloneThe risk or severity of adverse effects can be increased when Perampanel is combined with Nabilone.
NafcillinThe serum concentration of Perampanel can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Perampanel.
NefazodoneThe metabolism of Perampanel can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Perampanel can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Perampanel can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Perampanel can be decreased when it is combined with Nevirapine.
NilotinibThe metabolism of Perampanel can be decreased when combined with Nilotinib.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Perampanel.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Perampanel.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Perampanel.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Perampanel.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Perampanel.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Perampanel.
OlanzapineThe risk or severity of adverse effects can be increased when Perampanel is combined with Olanzapine.
OlaparibThe metabolism of Perampanel can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Perampanel.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Perampanel.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Perampanel.
OrlistatThe serum concentration of Perampanel can be decreased when it is combined with Orlistat.
OrphenadrinePerampanel may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Perampanel.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Perampanel.
OsimertinibThe serum concentration of Perampanel can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perampanel.
OxcarbazepineThe serum concentration of Oxcarbazepine can be increased when it is combined with Perampanel.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Perampanel.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Perampanel.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Perampanel.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Perampanel.
PalbociclibThe serum concentration of Perampanel can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Perampanel.
ParaldehydePerampanel may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Perampanel.
ParoxetineThe risk or severity of adverse effects can be increased when Perampanel is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Perampanel.
PentobarbitalThe serum concentration of Perampanel can be decreased when it is combined with Pentobarbital.
PentobarbitalThe risk or severity of adverse effects can be increased when Perampanel is combined with Pentobarbital.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Perampanel.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Perampanel.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Perampanel.
PhenobarbitalThe serum concentration of Perampanel can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Perampanel is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Perampanel.
PhenytoinThe serum concentration of Perampanel can be decreased when it is combined with Phenytoin.
PhenytoinThe risk or severity of adverse effects can be increased when Perampanel is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Perampanel.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Perampanel.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Perampanel.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Perampanel.
PomalidomideThe risk or severity of adverse effects can be increased when Perampanel is combined with Pomalidomide.
PosaconazoleThe metabolism of Perampanel can be decreased when combined with Posaconazole.
PramipexolePerampanel may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Perampanel.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Perampanel.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Perampanel.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Perampanel.
PrimidoneThe serum concentration of Perampanel can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Perampanel is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Perampanel.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perampanel.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Perampanel.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Perampanel.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Perampanel.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Perampanel.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Perampanel.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Perampanel.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Perampanel.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Perampanel.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Perampanel.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Perampanel.
RanolazineThe metabolism of Perampanel can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perampanel.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Perampanel.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Perampanel.
RifabutinThe serum concentration of Perampanel can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Perampanel can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Perampanel can be decreased when it is combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Perampanel.
RitonavirThe metabolism of Perampanel can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Perampanel.
RopinirolePerampanel may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Perampanel.
RotigotinePerampanel may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Perampanel.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Perampanel.
SaquinavirThe metabolism of Perampanel can be decreased when combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Perampanel.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Perampanel.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Perampanel.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Perampanel.
SertralineThe risk or severity of adverse effects can be increased when Perampanel is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perampanel.
SildenafilThe metabolism of Perampanel can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Perampanel can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Perampanel can be increased when it is combined with Simeprevir.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Perampanel.
St. John's WortThe serum concentration of Perampanel can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Perampanel is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perampanel.
SulfisoxazoleThe metabolism of Perampanel can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Perampanel.
SuvorexantThe risk or severity of adverse effects can be increased when Perampanel is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Perampanel.
TasimelteonThe risk or severity of adverse effects can be increased when Perampanel is combined with Tasimelteon.
TelaprevirThe metabolism of Perampanel can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Perampanel can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Perampanel.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Perampanel.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Perampanel.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Perampanel.
ThalidomidePerampanel may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Perampanel.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perampanel.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Perampanel.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Perampanel.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Perampanel.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Perampanel.
TiclopidineThe metabolism of Perampanel can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Perampanel.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Perampanel.
TocilizumabThe serum concentration of Perampanel can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Perampanel.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Perampanel.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Perampanel.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Perampanel.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Perampanel.
TrazodoneThe risk or severity of adverse effects can be increased when Perampanel is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Perampanel.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Perampanel.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Perampanel.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Perampanel.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Perampanel.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Perampanel.
VenlafaxineThe metabolism of Perampanel can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Perampanel can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Perampanel.
VilazodoneThe risk or severity of adverse effects can be increased when Perampanel is combined with Vilazodone.
VoriconazoleThe metabolism of Perampanel can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Perampanel is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Perampanel.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Perampanel.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Perampanel.
ZimelidineThe risk or severity of adverse effects can be increased when Perampanel is combined with Zimelidine.
ZiprasidoneThe metabolism of Perampanel can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Perampanel is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Perampanel.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Perampanel.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Perampanel.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Perampanel.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Perampanel.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Perampanel.
Food Interactions
  • Food slows perampanel's absorption rate but not extent.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIA1
Uniprot ID:
P42261
Molecular Weight:
101505.245 Da
References
  1. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y: Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011 Jul;52(7):1331-40. doi: 10.1111/j.1528-1167.2011.03109.x. Epub 2011 Jun 2. [PubMed:21635236 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
Comments
comments powered by Disqus
Drug created on May 21, 2013 19:44 / Updated on October 01, 2016 02:24